Status:
COMPLETED
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Lead Sponsor:
Rennes University Hospital
Conditions:
Ovarian Carcinoma
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical res...
Eligibility Criteria
Inclusion
- Pre-
- \- Patient with suspicious ovarian carcinoma using clinical data, biological data (ca125) and radiological data (CT)
- Pathological ovarian carcinoma diagnosed at pathological analysis after surgery.
- Neo adjuvant chemotherapy
Exclusion
- no neo-adjuvant chemotherapy
- no ovarian carcinoma at final pathological analysis
- less than 18 years old.
Key Trial Info
Start Date :
January 15 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 27 2019
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT02297958
Start Date
January 15 2015
End Date
July 27 2019
Last Update
August 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Gynécologie
Rennes, France